Invivyd Grants Stock Options to New Employees
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 06 2026
0mins
Source: Newsfilter
- Stock Option Grant: On April 1, 2026, Invivyd granted a total of 1,083,750 stock options to 16 newly hired non-executive employees as a material inducement for their employment, reflecting the company's commitment to attracting talent.
- Exercise Price Setting: The options have an exercise price of $1.33 per share, which matches the closing price of Invivyd's common stock on the grant date, facilitating potential capital appreciation for employees in the future.
- Vesting Arrangement: The options vest over four years, with 25% vesting on the first anniversary of the employee's start date and the remaining shares vesting in equal monthly installments, ensuring employees remain with the company to realize full benefits.
- Long-term Incentive Mechanism: With a 10-year term, the options are subject to the terms of the Invivyd 2026 Inducement Plan, aiming to enhance employee loyalty and motivation through long-term incentives, thereby driving sustainable business growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IVVD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IVVD
Wall Street analysts forecast IVVD stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.813
Low
10.00
Averages
10.00
High
10.00
Current: 0.813
Low
10.00
Averages
10.00
High
10.00
About IVVD
Invivyd, Inc. is a biopharmaceutical company. The Company’s proprietary INVYMAB platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats. The Company delivers antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, such as SARS-CoV-2. Its PEMGARDA (pemivibart) is the Company's first mAb to receive regulatory authorization and is designed to keep pace with SARS-CoV-2 viral evolution. PEMGARDA is used for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents. Its VYD2311 is optimized for neutralization potency against SARS-CoV-2 lineages such as BA.2.86 and JN.1. The Company also has additional anti-SARS-CoV-2 mAb candidates in discovery and pre-clinical characterization.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Invivyd Initiates Phase 3 Trial for VYD2311 Monoclonal Antibody
- Trial Launch: Invivyd announced that the first participant in its Phase 3 LIBERTY trial has been dosed with VYD2311, an investigational monoclonal antibody for COVID-19, marking a significant advancement in the company's antiviral treatment efforts.
- Trial Design Details: The LIBERTY trial is a randomized, double-blind study aiming to enroll approximately 210 participants aged 18 to 49, focusing on evaluating the safety of VYD2311 and its co-administration with an mRNA COVID-19 vaccine, highlighting the company's commitment to innovative therapies.
- Fast-Track Designation: VYD2311 has received fast-track designation from the U.S. FDA, indicating its potential importance in COVID-19 treatment and possibly accelerating its market entry, which could enhance the company's competitive position in the biopharmaceutical sector.
- Market Performance: Invivyd's stock has traded between $0.4830 and $3.070 over the past year, closing at $0.99, and despite recent declines, the clinical progress may positively influence future stock performance.
See More
Invivyd Launches LIBERTY Clinical Trial for VYD2311
- Trial Launch: Invivyd announced on June 9, 2026, that the first participants have been dosed in the LIBERTY Phase 3 clinical trial, which aims to evaluate the safety and tolerability of VYD2311 compared to the mRNA COVID-19 vaccine, potentially establishing a new standard of care for COVID-19 prevention.
- Recruitment Plan: The LIBERTY trial plans to enroll approximately 210 healthy adults aged 18 to 49, who will be randomized into three groups receiving either the mRNA vaccine, VYD2311 alone, or a combination of both, to assess the efficacy of different treatment regimens.
- Data Reporting Expectations: Depending on recruitment rates, Invivyd expects to report topline data from the LIBERTY trial in Q3 2026, coinciding with anticipated data from the pivotal DECLARATION trial, which could significantly impact VYD2311's regulatory filings.
- Strategic Importance: The LIBERTY trial is part of Invivyd's broader REVOLUTION clinical program, aimed at addressing concerns over vaccine side effects by offering a more tolerable COVID-19 prevention option, thereby enhancing the company's competitive position in the biopharmaceutical market.
See More
Invivyd Grants Stock Options to New Employees
- Stock Option Grant: On June 1, 2026, Invivyd granted stock options for a total of 513,500 shares to 17 newly hired non-executive employees as a material inducement for their employment, highlighting the company's commitment to attracting talent.
- Exercise Price Setting: The options have an exercise price of $1.22 per share, which matches the closing price of Invivyd's common stock on the grant date, facilitating potential capital appreciation for employees in the future.
- Vesting Arrangement: The options vest over four years, with 25% of the shares vesting on the first anniversary of the employee's start date and the remaining shares vesting in equal monthly installments, thereby enhancing employee loyalty while ensuring continuous service with the company.
- Long-term Incentive Mechanism: With a 10-year term, the options are subject to the terms of the Invivyd 2026 Inducement Plan, aiming to boost employee motivation and overall company performance through a long-term incentive structure.
See More
Invivyd's Q1 Revenue Misses Expectations, Shares Plummet
- Revenue Decline Factors: H.C. Wainwright & Co. noted that Invivyd's Q1 revenue of $13.7 million, while up 22% year-over-year, fell significantly short of Wall Street's $18 million estimate, indicating that seasonal factors may have impacted performance.
- Surge in R&D Expenses: The reported R&D expenses of $30.7 million exceeded expectations and are seen as a potential reason for the stock's decline, with these costs viewed as pivotal spending in preparation for the upcoming VYD2311 clinical readout.
- Price Target Reaffirmation: Despite revenue pressures, H.C. Wainwright reiterated a 'Buy' rating for Invivyd with a price target of $10, suggesting over 730% upside from current levels, reflecting confidence in the future product pipeline.
- Cautious Market Sentiment: While investor sentiment for IVVD remains neutral, concerns about its future performance have intensified, with some investors warning that without positive Phase 3 trial results, the stock could fall below $1, highlighting significant market uncertainty regarding the company's outlook.
See More
Invivyd Q1 2026 Earnings Call Highlights
- Accelerated Research Progress: Invivyd initiated the upsizing of its DECLARATION study in early April, with recruitment speed exceeding expectations; although recruitment was temporarily slowed due to anticipated summer COVID waves, it has now resumed at full speed, ensuring the project remains on schedule.
- Monitoring Time Reduction: The Independent Data Monitoring Committee recommended reducing the post-dose monitoring time for drug 2311 from 2 hours to 30 minutes based on safety data review, which could enhance patient acceptance and improve market adoption of the drug.
- Strong PEMGARDA Growth: The company reported a 22% year-over-year growth in PEMGARDA and plans to introduce a new COVID antibody, VYD2311, in the coming months, which, if approved, could significantly alter the market landscape and drive revenue growth.
- Healthy Cash Position: The company raised additional cash in April through market offerings, maintaining a strong cash position, and expects a return to normalized R&D spending as the pivotal trial for VYD2311 concludes, supporting future commercialization efforts.
See More
Invivyd Reports Q1 2026 Financial Results with Revenue Growth
- Earnings Highlights: Invivyd reported a Q1 2026 GAAP EPS of -$0.13, indicating a loss, yet revenue grew by 21.6% year-over-year to $13.74 million, reflecting a gradual recovery in the company's market position.
- Cash Position: As of the end of Q1 2026, Invivyd had $184.2 million in cash and cash equivalents, ensuring operational funding for the upcoming months, while also planning to raise approximately $20 million through its at-the-market offering facility, enhancing financial flexibility.
- Clinical Progress: Invivyd has made strides in its REVOLUTION clinical program, and while the market reacted positively to updates on its late-stage COVID therapy trial, analysts remain cautious about whether the trial's upsizing will instill the expected market confidence.
- Market Reaction: Following the earnings release, Invivyd's stock price increased, reflecting investor optimism regarding the company's future growth potential, although attention must remain on the final outcomes of its clinical trials and market acceptance.
See More
Invivyd Initiates Phase 3 Trial for VYD2311 Monoclonal Antibody
- Trial Launch: Invivyd announced that the first participant in its Phase 3 LIBERTY trial has been dosed with VYD2311, an investigational monoclonal antibody for COVID-19, marking a significant advancement in the company's antiviral treatment efforts.
- Trial Design Details: The LIBERTY trial is a randomized, double-blind study aiming to enroll approximately 210 participants aged 18 to 49, focusing on evaluating the safety of VYD2311 and its co-administration with an mRNA COVID-19 vaccine, highlighting the company's commitment to innovative therapies.
- Fast-Track Designation: VYD2311 has received fast-track designation from the U.S. FDA, indicating its potential importance in COVID-19 treatment and possibly accelerating its market entry, which could enhance the company's competitive position in the biopharmaceutical sector.
- Market Performance: Invivyd's stock has traded between $0.4830 and $3.070 over the past year, closing at $0.99, and despite recent declines, the clinical progress may positively influence future stock performance.
See More
Invivyd Launches LIBERTY Clinical Trial for VYD2311
- Trial Launch: Invivyd announced on June 9, 2026, that the first participants have been dosed in the LIBERTY Phase 3 clinical trial, which aims to evaluate the safety and tolerability of VYD2311 compared to the mRNA COVID-19 vaccine, potentially establishing a new standard of care for COVID-19 prevention.
- Recruitment Plan: The LIBERTY trial plans to enroll approximately 210 healthy adults aged 18 to 49, who will be randomized into three groups receiving either the mRNA vaccine, VYD2311 alone, or a combination of both, to assess the efficacy of different treatment regimens.
- Data Reporting Expectations: Depending on recruitment rates, Invivyd expects to report topline data from the LIBERTY trial in Q3 2026, coinciding with anticipated data from the pivotal DECLARATION trial, which could significantly impact VYD2311's regulatory filings.
- Strategic Importance: The LIBERTY trial is part of Invivyd's broader REVOLUTION clinical program, aimed at addressing concerns over vaccine side effects by offering a more tolerable COVID-19 prevention option, thereby enhancing the company's competitive position in the biopharmaceutical market.
See More
Invivyd Grants Stock Options to New Employees
- Stock Option Grant: On June 1, 2026, Invivyd granted stock options for a total of 513,500 shares to 17 newly hired non-executive employees as a material inducement for their employment, highlighting the company's commitment to attracting talent.
- Exercise Price Setting: The options have an exercise price of $1.22 per share, which matches the closing price of Invivyd's common stock on the grant date, facilitating potential capital appreciation for employees in the future.
- Vesting Arrangement: The options vest over four years, with 25% of the shares vesting on the first anniversary of the employee's start date and the remaining shares vesting in equal monthly installments, thereby enhancing employee loyalty while ensuring continuous service with the company.
- Long-term Incentive Mechanism: With a 10-year term, the options are subject to the terms of the Invivyd 2026 Inducement Plan, aiming to boost employee motivation and overall company performance through a long-term incentive structure.
See More
Invivyd's Q1 Revenue Misses Expectations, Shares Plummet
- Revenue Decline Factors: H.C. Wainwright & Co. noted that Invivyd's Q1 revenue of $13.7 million, while up 22% year-over-year, fell significantly short of Wall Street's $18 million estimate, indicating that seasonal factors may have impacted performance.
- Surge in R&D Expenses: The reported R&D expenses of $30.7 million exceeded expectations and are seen as a potential reason for the stock's decline, with these costs viewed as pivotal spending in preparation for the upcoming VYD2311 clinical readout.
- Price Target Reaffirmation: Despite revenue pressures, H.C. Wainwright reiterated a 'Buy' rating for Invivyd with a price target of $10, suggesting over 730% upside from current levels, reflecting confidence in the future product pipeline.
- Cautious Market Sentiment: While investor sentiment for IVVD remains neutral, concerns about its future performance have intensified, with some investors warning that without positive Phase 3 trial results, the stock could fall below $1, highlighting significant market uncertainty regarding the company's outlook.
See More
Invivyd Q1 2026 Earnings Call Highlights
- Accelerated Research Progress: Invivyd initiated the upsizing of its DECLARATION study in early April, with recruitment speed exceeding expectations; although recruitment was temporarily slowed due to anticipated summer COVID waves, it has now resumed at full speed, ensuring the project remains on schedule.
- Monitoring Time Reduction: The Independent Data Monitoring Committee recommended reducing the post-dose monitoring time for drug 2311 from 2 hours to 30 minutes based on safety data review, which could enhance patient acceptance and improve market adoption of the drug.
- Strong PEMGARDA Growth: The company reported a 22% year-over-year growth in PEMGARDA and plans to introduce a new COVID antibody, VYD2311, in the coming months, which, if approved, could significantly alter the market landscape and drive revenue growth.
- Healthy Cash Position: The company raised additional cash in April through market offerings, maintaining a strong cash position, and expects a return to normalized R&D spending as the pivotal trial for VYD2311 concludes, supporting future commercialization efforts.
See More
Invivyd Reports Q1 2026 Financial Results with Revenue Growth
- Earnings Highlights: Invivyd reported a Q1 2026 GAAP EPS of -$0.13, indicating a loss, yet revenue grew by 21.6% year-over-year to $13.74 million, reflecting a gradual recovery in the company's market position.
- Cash Position: As of the end of Q1 2026, Invivyd had $184.2 million in cash and cash equivalents, ensuring operational funding for the upcoming months, while also planning to raise approximately $20 million through its at-the-market offering facility, enhancing financial flexibility.
- Clinical Progress: Invivyd has made strides in its REVOLUTION clinical program, and while the market reacted positively to updates on its late-stage COVID therapy trial, analysts remain cautious about whether the trial's upsizing will instill the expected market confidence.
- Market Reaction: Following the earnings release, Invivyd's stock price increased, reflecting investor optimism regarding the company's future growth potential, although attention must remain on the final outcomes of its clinical trials and market acceptance.
See More
